CAMP4 THERAPEUTICS CORPORATION CAMP
4.00 USD -0.10 (-2.44%)
Regular-session close
4.00 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
3.74 Day range 4.25
2.90 52-week range 7.75
- YTD
- -34.75%
- 1 year
- +7.82%
News
globenewswire.com CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of…benzinga.com Camp4 Therapeutics Q3 EPS $(0.37) Misses $(0.18) Estimate, Sales $1.899M Beat $1.850M Estimate Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.18) by 105.56 percent. This is a 32.73 percent increase over losses…
benzinga.com CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002Company…
benzinga.com Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10 Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.
